文献速递泌尿系结石

选择性对比经验性药物预防治疗与肾结石复发比较

Comparison of Selective Versus Empiric Pharmacologic Preventative Therapy With Kidney Stone Recurrence.
PubMed 文献 · Urology · 2020-12-19

本研究利用2008-2017年工作年龄成人肾结石患者的医疗索赔数据,评估基于24小时尿液检测指导的选择性药物治疗与经验性药物治疗对结石相关事件复发的影响。共纳入10,125例患者,其中27%接受选择性治疗,73%接受经验性治疗。调整混杂因素后,两组结石相关事件风险无显著差异(HR 0.97,95%CI 0.84-1.12),且急诊就诊、住院和手术频率均无差异。

要点

  • 选择性治疗组与经验性治疗组的结石相关事件风险无显著差异。
  • 两组急诊就诊、住院和手术频率均无显著差异。
  • 更高的药物依从性和较大年龄与较低结石事件风险相关。

核心结论

  • 与经验性治疗相比,基于24小时尿液检测指导的预防性药物治疗平均不降低结石相关事件风险。

研究设计与样本

  • 利用2008-2017年工作年龄成人肾结石患者的医疗索赔数据,识别接受噻嗪类、碱剂或别嘌呤醇(统称预防性药物治疗)的患者。
  • 根据启动预防性药物治疗前是否进行24小时尿液检测,分为选择性治疗组(2744例,27%)和经验性治疗组(7381例,73%)。
  • 采用生存分析评估启动预防性药物治疗后至首次结石相关事件(包括急诊就诊、住院和手术)的时间,随访至2年。

主要发现

  • 调整社会人口学因素、合并症、药物类别和依从性后,选择性治疗组与经验性治疗组结石相关事件风险无差异(HR 0.97,95%CI 0.84-1.12)。
  • 两组急诊就诊、住院和手术频率分别比较均无差异。

临床怎么用

  • 对于肾结石患者,经验性预防性药物治疗与基于24小时尿液检测指导的选择性治疗在平均效果上无显著差异,提示需识别真正能从24小时尿液检测中获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the effectiveness of an empiric approach to metabolic stone prevention. METHODS: Using medical claims from a cohort of working age adults with kidney stone diagnoses (2008-2017), we identified the subset who were prescribed thiazides, alkali therapy, or allopurinol-collectively known as preventive pharmacologic therapy (PPT). We distinguished between those who had 24-hour urine testing prior to initiating PPT (selective therapy) from those without it (empiric therapy). We conducted a survival analysis for time to first recurrence for stone-related events, including ED visits, hospitalizations, and surgery, up to 2 years after initiating PPT. RESULTS: Of 10,125 patients identified, 2744 (27%) and 7381 (73%) received selective and empiric therapy, respectively. The overall frequency of any stone-related event was 11%, and this did not differ between the 2 groups on bivariate analysis (P = .29). After adjusting for sociodemographic factors, comorbidities, medication class, and adherence, there was no difference in the hazard of a stone-related event between the selective and empiric therapy groups (hazard ratio, 0.97; 95% confidence interval, 0.84-1.12). When considered individually, the frequency of ED visits, hospitalizations, and surgeries did not differ between groups. Greater adherence to PPT and older age were associated with a lower hazard of a stone-related event (both P < .05). CONCLUSION: Compared to empiric therapy, PPT guided by 24-hour urine testing, on average, is not associated with a lower hazard of a stone-related event. These results suggest a need to identify kidney stone patients who benefit from 24-hour urine testing.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Hsi RS, Yan PL, Goldfarb DS, et al. Comparison of Selective Versus Empiric Pharmacologic Preventative Therapy With Kidney Stone Recurrence. Urology. 2020. PMID: 33352163. doi:10.1016/j.urology.2020.11.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。